The global Biosimilars Market Size is on a high-growth trajectory, with a market value of USD 29.51 billion in 2023, projected to reach an impressive USD 127.92 billion by 2032. This substantial expansion represents a compound annual growth rate (CAGR) of 17.7% over the forecast period from 2024 to 2032, according to a newly released industry report.
Biosimilars are biologic medical products that are nearly identical to an original reference product but manufactured by a different company once the original product's patent expires. As healthcare systems worldwide grapple with rising treatment costs and growing patient populations, biosimilars offer a cost-effective alternative without compromising therapeutic efficacy.
Get Free Sample Report on Biosimilars Market size
https://www.snsinsider.com/sample-request/2941
Key Drivers of Growth
- Patent Expirations of Blockbuster Biologics:
The expiration of patents on major biologic drugs such as Humira (adalimumab), Enbrel (etanercept), and Herceptin (trastuzumab) has opened the door for biosimilar manufacturers to enter the market. This shift is rapidly expanding treatment accessibility and intensifying competition in the pharmaceutical landscape. - Rising Prevalence of Chronic and Autoimmune Diseases:
Conditions such as cancer, rheumatoid arthritis, inflammatory bowel disease (IBD), and diabetes are on the rise globally. Biosimilars are increasingly being prescribed for these diseases due to their proven safety, efficacy, and affordability, further driving demand. - Cost Savings and Healthcare Sustainability:
Governments and private insurers are embracing biosimilars to reduce healthcare costs and enhance sustainability. Biosimilars provide a significant price advantage compared to their originator biologics, enabling broader patient access. - Regulatory Support and Streamlined Approvals:
Agencies such as the U.S. FDA, EMA, and WHO have developed clear regulatory pathways to ensure the safe and timely approval of biosimilars. These frameworks are contributing to the accelerated market entry and widespread adoption of biosimilar products. - Growing Acceptance Among Healthcare Providers:
Physicians, pharmacists, and patients are increasingly recognizing the clinical equivalence of biosimilars, especially as real-world evidence and post-marketing surveillance data continue to validate their efficacy and safety.
Key Market Segments
By Type
- Human growth hormone
- Erythropoietin
- Monoclonal antibodies
- Insulin
- Granulocyte-Colony Stimulating Factor
By Application
- Blood disorders
- Oncology diseases
- Chronic and autoimmune diseases
Major Biosimilars Companies
- Reddy’s Laboratories
- Sandoz
- Coherus Biosciences
- Viatris
- Bio-Thera Solutions
- Reliance Life Sciences
- Intas Pharma
- Celltrion
- Zydus Cadila
- Lupin Pharma
- Samsung Bioepis
- Pfizer
- Apobiologix
- Amgen
- Teva Pharmaceuticals
- Fresenius Kabi
- Biocon Ltd
- Biocad and others.
Recent Strategic Developments
- Pfizer received FDA approval for a biosimilar to adalimumab in late 2023 and is expanding its biosimilar pipeline targeting oncology and inflammation.
- Amgen launched biosimilars of both bevacizumab and trastuzumab, gaining significant U.S. and European market share.
- Biocon and Viatris extended their partnership with plans to launch multiple biosimilars in global markets by 2026.
- Sandoz (Novartis) announced a USD 400 million investment in a new biologics manufacturing facility to support growing biosimilar demand.
Market Opportunities and Challenges
Opportunities
- Emerging Markets Expansion: Untapped markets in Latin America, Southeast Asia, and Africa represent significant growth potential for biosimilar manufacturers.
- Patent Cliffs in New Therapeutic Areas: With more biologics losing exclusivity in areas such as ophthalmology and endocrinology, biosimilars are set to diversify across therapeutic domains.
- Digital Health Integration: Innovations in electronic health records (EHRs), e-prescriptions, and patient education platforms are aiding biosimilar uptake by simplifying prescribing and monitoring processes.
Challenges
- Market Entry Barriers: High development costs, stringent regulatory requirements, and the need for robust pharmacovigilance systems remain key hurdles for new entrants.
- Physician Reluctance in Some Markets: While acceptance is growing, some healthcare providers remain hesitant to prescribe biosimilars due to concerns about immunogenicity or switching patients from originator biologics.
- Litigation and Patent Disputes: Legal challenges from originator companies can delay biosimilar launches and increase operational complexity.
Future Outlook
The next decade is expected to witness an explosion in biosimilar launches, supported by favorable regulatory reforms, technological innovation, and increased patient demand. The combination of clinical value, economic efficiency, and expanded access makes biosimilars an essential component of the future of global healthcare.
With a projected leap from USD 29.51 billion in 2023 to USD 127.92 billion by 2032, the biosimilars market offers immense opportunities for stakeholders ranging from manufacturers and healthcare providers to policy-makers and investors.
About US
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)